Related Experiment Video
Updated: May 3, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
IGFBP-3 promoter polymorphism -202A>C (rs2854774) contributes to prostate cancer risk: evidence based on 9,482
1Department of Urology, The Changshu Hospital Affiliated to Soochow University, Changshu, China.
Objective:
Evidence suggests that insulin-like growth factor-binding protein 3 (IGFBP-3) might play a role in the carcinogenesis of prostate cancer (PCa). To date, several studies have been conducted to investigate the association between IGFBP-3 -202A>C polymorphism and PCa risk in humans. However, the results remain inconclusive and inconsistent. Hence, we performed a meta-analysis of all eligible case-control studies.
Methods:
We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association.
Results:
16 studies from 10 articles that included a total of 4,602 PCa cases and 4,880 controls were included in the meta-analysis. The results showed that the IGFBP-3 -A>C polymorphism was associated with a significant increase in PCa risk. The variant homozygote genotype CC of IGFBP-3 -202A>C polymorphism was associated with a significantly increased risk in homozygote comparison (OR = 1.22, 95% CI = 1.07-1.38, I(2) = 36.10%) and recessive model (OR = 1.11, 95% CI = 1.00-1.22, I(2) = 15.60%). In the stratified analysis, the risk remained for studies in Asian men and hospital-based studies.
Conclusions:
These results suggested that the IGFBP-3 -202A>C polymorphism might contribute to PCa susceptibility, especially in Asian men and hospital-based studies. Further studies are needed to confirm the relationship.
More Related Videos
11:35Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
Published on: August 21, 2016
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Single Nucleotide Polymorphisms-SNPs
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
The Ras Gene
Ras is a...